Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 51 | 2023 | 980 | 5.290 |
Why?
|
HIV-1 | 23 | 2022 | 440 | 2.170 |
Why?
|
Anti-HIV Agents | 14 | 2022 | 171 | 1.980 |
Why?
|
Vaginosis, Bacterial | 8 | 2007 | 30 | 1.090 |
Why?
|
Antiretroviral Therapy, Highly Active | 7 | 2020 | 140 | 0.950 |
Why?
|
Lactobacillus | 3 | 2008 | 19 | 0.850 |
Why?
|
Vagina | 6 | 2008 | 46 | 0.830 |
Why?
|
Continuity of Patient Care | 2 | 2020 | 28 | 0.810 |
Why?
|
Mass Screening | 2 | 2020 | 177 | 0.800 |
Why?
|
RNA, Viral | 9 | 2019 | 149 | 0.800 |
Why?
|
Electronic Health Records | 2 | 2022 | 66 | 0.730 |
Why?
|
HIV Antibodies | 6 | 2022 | 42 | 0.690 |
Why?
|
Patient Compliance | 2 | 2018 | 164 | 0.670 |
Why?
|
Humans | 71 | 2023 | 29361 | 0.650 |
Why?
|
Reminder Systems | 1 | 2018 | 5 | 0.640 |
Why?
|
Appointments and Schedules | 1 | 2018 | 13 | 0.640 |
Why?
|
Adult | 38 | 2020 | 8604 | 0.610 |
Why?
|
Female | 47 | 2023 | 16211 | 0.600 |
Why?
|
Patient Education as Topic | 1 | 2018 | 162 | 0.570 |
Why?
|
Viral Load | 11 | 2020 | 199 | 0.550 |
Why?
|
Melioidosis | 1 | 2015 | 3 | 0.550 |
Why?
|
Burkholderia pseudomallei | 1 | 2015 | 3 | 0.550 |
Why?
|
Travel | 1 | 2015 | 13 | 0.540 |
Why?
|
HIV | 5 | 2023 | 92 | 0.480 |
Why?
|
Middle Aged | 26 | 2023 | 9823 | 0.450 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2023 | 170 | 0.440 |
Why?
|
Gardnerella vaginalis | 4 | 2008 | 6 | 0.440 |
Why?
|
Mycoplasma hominis | 4 | 2008 | 6 | 0.440 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2011 | 30 | 0.430 |
Why?
|
Anti-Bacterial Agents | 1 | 2015 | 402 | 0.430 |
Why?
|
Candidiasis, Vulvovaginal | 3 | 2007 | 6 | 0.410 |
Why?
|
Male | 32 | 2023 | 15637 | 0.410 |
Why?
|
HIV Antigens | 2 | 2022 | 22 | 0.410 |
Why?
|
CD4 Lymphocyte Count | 12 | 2020 | 152 | 0.390 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2002 | 90 | 0.370 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2019 | 15 | 0.340 |
Why?
|
Lamivudine | 2 | 2019 | 19 | 0.340 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2000 | 46 | 0.330 |
Why?
|
Interleukin-8 | 2 | 2008 | 32 | 0.330 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 553 | 0.320 |
Why?
|
Polymerase Chain Reaction | 2 | 2005 | 161 | 0.320 |
Why?
|
Candidiasis | 1 | 2008 | 17 | 0.320 |
Why?
|
Candida albicans | 1 | 2008 | 22 | 0.320 |
Why?
|
Trichomonas Infections | 1 | 2007 | 3 | 0.320 |
Why?
|
Immunoglobulin G | 3 | 2023 | 129 | 0.310 |
Why?
|
Cytomegalovirus Infections | 2 | 2023 | 79 | 0.310 |
Why?
|
Adolescent | 6 | 2019 | 2280 | 0.310 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2004 | 24 | 0.300 |
Why?
|
Cervix Uteri | 4 | 2002 | 38 | 0.300 |
Why?
|
Urban Population | 2 | 2019 | 143 | 0.300 |
Why?
|
Interleukin-2 | 2 | 2008 | 66 | 0.290 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2005 | 215 | 0.290 |
Why?
|
Chicago | 6 | 2023 | 865 | 0.280 |
Why?
|
Oxazines | 3 | 2019 | 8 | 0.280 |
Why?
|
Coronary Artery Disease | 2 | 2023 | 123 | 0.270 |
Why?
|
Antibodies, Viral | 5 | 2022 | 87 | 0.270 |
Why?
|
Histiocytic Necrotizing Lymphadenitis | 1 | 2004 | 2 | 0.260 |
Why?
|
Nevirapine | 2 | 2004 | 3 | 0.260 |
Why?
|
Hydroxychloroquine | 1 | 2004 | 9 | 0.260 |
Why?
|
Drug Therapy, Combination | 6 | 2019 | 241 | 0.260 |
Why?
|
Hepatitis C | 2 | 2023 | 65 | 0.260 |
Why?
|
Hyperlipidemias | 1 | 2004 | 18 | 0.250 |
Why?
|
Lipids | 1 | 2004 | 36 | 0.250 |
Why?
|
AIDS Vaccines | 1 | 2004 | 14 | 0.250 |
Why?
|
Insulin Resistance | 1 | 2004 | 60 | 0.250 |
Why?
|
Interleukin-12 | 1 | 2004 | 38 | 0.240 |
Why?
|
Immunity, Cellular | 2 | 2023 | 65 | 0.240 |
Why?
|
Genitalia, Female | 5 | 2005 | 28 | 0.240 |
Why?
|
Sexually Transmitted Diseases | 1 | 2023 | 16 | 0.230 |
Why?
|
Emergency Service, Hospital | 3 | 2023 | 221 | 0.230 |
Why?
|
HIV-2 | 1 | 2022 | 10 | 0.220 |
Why?
|
Sexual and Gender Minorities | 1 | 2023 | 25 | 0.220 |
Why?
|
Vaccines | 1 | 2022 | 12 | 0.220 |
Why?
|
Immunoassay | 1 | 2022 | 43 | 0.220 |
Why?
|
Interleukin-6 | 2 | 2002 | 108 | 0.220 |
Why?
|
Arginine | 1 | 2002 | 18 | 0.220 |
Why?
|
Immunity | 1 | 2002 | 24 | 0.220 |
Why?
|
Pre-Exposure Prophylaxis | 1 | 2022 | 5 | 0.210 |
Why?
|
beta Catenin | 1 | 2022 | 46 | 0.200 |
Why?
|
Gene Expression Regulation | 3 | 2020 | 284 | 0.200 |
Why?
|
Liver Failure, Acute | 1 | 2000 | 1 | 0.200 |
Why?
|
Needlestick Injuries | 1 | 2000 | 2 | 0.200 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2000 | 13 | 0.190 |
Why?
|
Occupational Exposure | 1 | 2000 | 25 | 0.190 |
Why?
|
Receptors, IgG | 1 | 2020 | 19 | 0.190 |
Why?
|
Dideoxynucleosides | 1 | 2000 | 4 | 0.190 |
Why?
|
Genital Diseases, Female | 2 | 1997 | 10 | 0.190 |
Why?
|
Wnt Proteins | 1 | 2020 | 16 | 0.190 |
Why?
|
Glycoproteins | 1 | 2020 | 58 | 0.190 |
Why?
|
HIV Core Protein p24 | 3 | 2018 | 29 | 0.190 |
Why?
|
T-Lymphocyte Subsets | 1 | 2020 | 86 | 0.190 |
Why?
|
Health Plan Implementation | 1 | 2020 | 8 | 0.180 |
Why?
|
Wnt Signaling Pathway | 1 | 2020 | 33 | 0.180 |
Why?
|
Cardiovascular Diseases | 2 | 2023 | 401 | 0.180 |
Why?
|
Zidovudine | 3 | 1999 | 39 | 0.170 |
Why?
|
Program Development | 1 | 2019 | 69 | 0.170 |
Why?
|
Program Evaluation | 1 | 2019 | 132 | 0.170 |
Why?
|
Biomarkers | 2 | 2023 | 692 | 0.170 |
Why?
|
Vaginal Smears | 3 | 2007 | 17 | 0.160 |
Why?
|
Thailand | 1 | 2018 | 11 | 0.160 |
Why?
|
3' Untranslated Regions | 1 | 2017 | 3 | 0.160 |
Why?
|
Proprotein Convertase 9 | 1 | 2017 | 2 | 0.160 |
Why?
|
Coinfection | 1 | 2017 | 29 | 0.150 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2022 | 220 | 0.150 |
Why?
|
United States | 5 | 2023 | 2332 | 0.150 |
Why?
|
Pilot Projects | 4 | 2019 | 394 | 0.150 |
Why?
|
Patient Discharge | 1 | 2018 | 149 | 0.140 |
Why?
|
Hepatitis C, Chronic | 1 | 2017 | 78 | 0.140 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 306 | 0.140 |
Why?
|
Censuses | 1 | 2016 | 6 | 0.140 |
Why?
|
Simplexvirus | 2 | 2006 | 9 | 0.140 |
Why?
|
Leukocytes, Mononuclear | 2 | 2011 | 97 | 0.140 |
Why?
|
Mexico | 1 | 2015 | 18 | 0.140 |
Why?
|
Phylogeny | 1 | 2015 | 63 | 0.130 |
Why?
|
Neuroaspergillosis | 1 | 2015 | 2 | 0.130 |
Why?
|
Brain Abscess | 1 | 2015 | 7 | 0.130 |
Why?
|
Triazoles | 1 | 2015 | 30 | 0.130 |
Why?
|
Antifungal Agents | 1 | 2015 | 36 | 0.130 |
Why?
|
Residence Characteristics | 1 | 2016 | 217 | 0.120 |
Why?
|
Cytokines | 4 | 2008 | 348 | 0.120 |
Why?
|
Prospective Studies | 5 | 2011 | 1812 | 0.120 |
Why?
|
Complement System Proteins | 3 | 1998 | 15 | 0.120 |
Why?
|
AIDS Serodiagnosis | 1 | 1993 | 6 | 0.120 |
Why?
|
Retrospective Studies | 6 | 2023 | 3273 | 0.120 |
Why?
|
Pneumocystis Infections | 1 | 1992 | 1 | 0.110 |
Why?
|
Pentamidine | 1 | 1992 | 2 | 0.110 |
Why?
|
Choroiditis | 1 | 1992 | 2 | 0.110 |
Why?
|
Treatment Failure | 3 | 2019 | 159 | 0.110 |
Why?
|
Measles virus | 1 | 1991 | 1 | 0.100 |
Why?
|
Measles | 1 | 1991 | 2 | 0.100 |
Why?
|
Acyclovir | 1 | 1991 | 5 | 0.100 |
Why?
|
Retinitis | 1 | 1991 | 3 | 0.100 |
Why?
|
Fluconazole | 1 | 1991 | 7 | 0.100 |
Why?
|
Cryptococcosis | 1 | 1991 | 5 | 0.100 |
Why?
|
Histoplasmosis | 1 | 1991 | 8 | 0.100 |
Why?
|
Meningitis | 1 | 1991 | 11 | 0.100 |
Why?
|
Fatty Alcohols | 1 | 2011 | 6 | 0.100 |
Why?
|
Double-Blind Method | 4 | 2011 | 503 | 0.100 |
Why?
|
Anticholesteremic Agents | 1 | 2011 | 17 | 0.100 |
Why?
|
Logistic Models | 2 | 2011 | 407 | 0.100 |
Why?
|
Medically Underserved Area | 1 | 2011 | 13 | 0.100 |
Why?
|
HLA-DR Antigens | 1 | 2011 | 26 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 22 | 0.100 |
Why?
|
Pregnancy | 2 | 2011 | 404 | 0.100 |
Why?
|
Pandemics | 2 | 2023 | 236 | 0.100 |
Why?
|
Postpartum Period | 1 | 2011 | 24 | 0.100 |
Why?
|
Dyslipidemias | 1 | 2011 | 23 | 0.100 |
Why?
|
Infant, Newborn | 2 | 2011 | 604 | 0.090 |
Why?
|
Neutrophils | 1 | 2011 | 117 | 0.090 |
Why?
|
Aged | 7 | 2018 | 9447 | 0.090 |
Why?
|
Pharmacy Service, Hospital | 1 | 2009 | 9 | 0.090 |
Why?
|
HIV Seropositivity | 3 | 2019 | 95 | 0.090 |
Why?
|
Cholesterol, HDL | 2 | 2011 | 27 | 0.090 |
Why?
|
Cholesterol, LDL | 2 | 2011 | 30 | 0.090 |
Why?
|
Pyomyositis | 1 | 2009 | 5 | 0.090 |
Why?
|
Blastomyces | 1 | 2009 | 8 | 0.090 |
Why?
|
Triglycerides | 2 | 2011 | 41 | 0.090 |
Why?
|
Extremities | 1 | 2009 | 31 | 0.090 |
Why?
|
Blastomycosis | 1 | 2009 | 16 | 0.090 |
Why?
|
Gene Expression Regulation, Viral | 2 | 1999 | 14 | 0.090 |
Why?
|
Pyridones | 2 | 2019 | 13 | 0.080 |
Why?
|
Treatment Outcome | 4 | 2016 | 3476 | 0.080 |
Why?
|
Young Adult | 3 | 2020 | 1935 | 0.080 |
Why?
|
Recombinant Proteins | 3 | 2008 | 251 | 0.080 |
Why?
|
Colony Count, Microbial | 2 | 2005 | 23 | 0.080 |
Why?
|
Vaginal Douching | 2 | 2005 | 9 | 0.080 |
Why?
|
Calcinosis | 1 | 2008 | 47 | 0.080 |
Why?
|
Flow Cytometry | 3 | 2020 | 199 | 0.080 |
Why?
|
Papanicolaou Test | 1 | 2007 | 10 | 0.080 |
Why?
|
Piperazines | 2 | 2019 | 90 | 0.080 |
Why?
|
Cytological Techniques | 1 | 2007 | 14 | 0.080 |
Why?
|
Matched-Pair Analysis | 1 | 2007 | 20 | 0.080 |
Why?
|
Seroepidemiologic Studies | 2 | 2004 | 20 | 0.070 |
Why?
|
Papillomavirus Infections | 2 | 2005 | 37 | 0.070 |
Why?
|
Monocytes | 2 | 2005 | 116 | 0.070 |
Why?
|
Hepatitis | 1 | 2006 | 9 | 0.070 |
Why?
|
Bone Marrow Transplantation | 1 | 2006 | 34 | 0.070 |
Why?
|
Membrane Glycoproteins | 2 | 2005 | 101 | 0.070 |
Why?
|
Cohort Studies | 3 | 2004 | 1939 | 0.070 |
Why?
|
Gentian Violet | 1 | 2005 | 4 | 0.070 |
Why?
|
Phenazines | 1 | 2005 | 6 | 0.070 |
Why?
|
Comorbidity | 1 | 2007 | 497 | 0.070 |
Why?
|
Cross-Sectional Studies | 5 | 2017 | 965 | 0.070 |
Why?
|
DNA, Bacterial | 1 | 2005 | 48 | 0.070 |
Why?
|
Trichomonas Vaginitis | 1 | 2005 | 3 | 0.070 |
Why?
|
Virus Activation | 2 | 2022 | 12 | 0.070 |
Why?
|
Receptors, Cell Surface | 1 | 2005 | 50 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2002 | 33 | 0.070 |
Why?
|
Mycoplasma Infections | 1 | 2004 | 3 | 0.060 |
Why?
|
HIV Long Terminal Repeat | 3 | 1999 | 16 | 0.060 |
Why?
|
Candida | 1 | 2004 | 16 | 0.060 |
Why?
|
Antimalarials | 1 | 2004 | 8 | 0.060 |
Why?
|
Fasting | 1 | 2004 | 13 | 0.060 |
Why?
|
Incidence | 1 | 2007 | 756 | 0.060 |
Why?
|
Placebos | 2 | 2002 | 77 | 0.060 |
Why?
|
Sample Size | 1 | 2004 | 25 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2006 | 125 | 0.060 |
Why?
|
Virus Latency | 2 | 2022 | 17 | 0.060 |
Why?
|
Injections, Intradermal | 1 | 2004 | 2 | 0.060 |
Why?
|
Vaccines, Synthetic | 1 | 2004 | 3 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2004 | 64 | 0.060 |
Why?
|
Cholesterol | 1 | 2004 | 49 | 0.060 |
Why?
|
HLA Antigens | 1 | 2004 | 17 | 0.060 |
Why?
|
Adjuvants, Immunologic | 1 | 2004 | 26 | 0.060 |
Why?
|
Regression Analysis | 1 | 2004 | 298 | 0.060 |
Why?
|
Insulin | 1 | 2004 | 92 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2005 | 521 | 0.060 |
Why?
|
Blood Glucose | 1 | 2004 | 112 | 0.060 |
Why?
|
CD28 Antigens | 1 | 2003 | 16 | 0.060 |
Why?
|
Virus Replication | 1 | 2003 | 92 | 0.060 |
Why?
|
Homosexuality, Male | 1 | 2023 | 25 | 0.060 |
Why?
|
Thymus Gland | 1 | 2003 | 23 | 0.060 |
Why?
|
Skin | 1 | 2004 | 117 | 0.060 |
Why?
|
Immunity, Humoral | 1 | 2023 | 6 | 0.060 |
Why?
|
Glycosylation | 1 | 2022 | 24 | 0.060 |
Why?
|
Antibody Formation | 1 | 2022 | 40 | 0.060 |
Why?
|
Antibodies | 1 | 2022 | 65 | 0.050 |
Why?
|
Cytomegalovirus | 1 | 2023 | 76 | 0.050 |
Why?
|
Etanercept | 1 | 2002 | 23 | 0.050 |
Why?
|
Liver | 1 | 2004 | 173 | 0.050 |
Why?
|
Immunotherapy | 1 | 2022 | 62 | 0.050 |
Why?
|
Drug Interactions | 1 | 2002 | 67 | 0.050 |
Why?
|
Enhancer Elements, Genetic | 2 | 1999 | 11 | 0.050 |
Why?
|
Cell Count | 1 | 2002 | 99 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2002 | 53 | 0.050 |
Why?
|
Sexual Behavior | 2 | 2002 | 66 | 0.050 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2002 | 28 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2017 | 1442 | 0.050 |
Why?
|
Immunologic Factors | 1 | 2002 | 39 | 0.050 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2021 | 17 | 0.050 |
Why?
|
Mass Spectrometry | 1 | 2021 | 41 | 0.050 |
Why?
|
Killer Cells, Natural | 1 | 2002 | 91 | 0.050 |
Why?
|
Antibodies, Neutralizing | 1 | 2021 | 27 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2002 | 125 | 0.050 |
Why?
|
NF-kappa B | 2 | 1999 | 107 | 0.050 |
Why?
|
HIV Seronegativity | 2 | 1998 | 43 | 0.050 |
Why?
|
Mutation | 2 | 2019 | 383 | 0.050 |
Why?
|
Antigens, Differentiation | 1 | 2001 | 20 | 0.050 |
Why?
|
Risk Factors | 4 | 2008 | 2446 | 0.050 |
Why?
|
Calcium-Binding Proteins | 1 | 2001 | 22 | 0.050 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2000 | 11 | 0.050 |
Why?
|
Alkynes | 1 | 2000 | 9 | 0.050 |
Why?
|
Cell Separation | 1 | 2020 | 42 | 0.050 |
Why?
|
Benzoxazines | 1 | 2000 | 9 | 0.050 |
Why?
|
Cyclopropanes | 1 | 2000 | 25 | 0.050 |
Why?
|
Body Composition | 1 | 2000 | 56 | 0.050 |
Why?
|
Safety | 1 | 2000 | 45 | 0.050 |
Why?
|
Cell Line | 4 | 2005 | 299 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2000 | 36 | 0.050 |
Why?
|
Adipose Tissue | 1 | 2000 | 74 | 0.050 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2020 | 59 | 0.050 |
Why?
|
Fever | 1 | 2000 | 40 | 0.050 |
Why?
|
Biological Factors | 1 | 1999 | 9 | 0.050 |
Why?
|
Liver Transplantation | 1 | 2000 | 79 | 0.040 |
Why?
|
Esophageal Diseases | 1 | 1999 | 4 | 0.040 |
Why?
|
Thalidomide | 1 | 1999 | 5 | 0.040 |
Why?
|
Ulcer | 1 | 1999 | 7 | 0.040 |
Why?
|
Bacterial Vaccines | 1 | 1999 | 4 | 0.040 |
Why?
|
Streptococcus pneumoniae | 1 | 1999 | 6 | 0.040 |
Why?
|
Pneumococcal Infections | 1 | 1999 | 9 | 0.040 |
Why?
|
DNA | 1 | 1999 | 125 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2019 | 37 | 0.040 |
Why?
|
Acute Disease | 1 | 2020 | 226 | 0.040 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 16 | 0.040 |
Why?
|
Immunoglobulin A, Secretory | 1 | 1997 | 6 | 0.040 |
Why?
|
Body Fluids | 1 | 1997 | 19 | 0.040 |
Why?
|
Menstrual Cycle | 1 | 1997 | 27 | 0.040 |
Why?
|
Influenza Vaccines | 1 | 1997 | 11 | 0.040 |
Why?
|
Disease Progression | 2 | 2003 | 788 | 0.040 |
Why?
|
Complement Pathway, Classical | 1 | 1996 | 5 | 0.040 |
Why?
|
Viremia | 1 | 1996 | 36 | 0.040 |
Why?
|
Environment Design | 1 | 2016 | 10 | 0.040 |
Why?
|
Social Segregation | 1 | 2016 | 8 | 0.040 |
Why?
|
Forecasting | 1 | 2016 | 117 | 0.030 |
Why?
|
Models, Statistical | 1 | 2016 | 132 | 0.030 |
Why?
|
Medication Adherence | 1 | 2016 | 78 | 0.030 |
Why?
|
Tablets | 1 | 2015 | 8 | 0.030 |
Why?
|
Voriconazole | 1 | 2015 | 8 | 0.030 |
Why?
|
Poverty | 1 | 2016 | 96 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 38 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2008 | 1829 | 0.030 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1995 | 32 | 0.030 |
Why?
|
Survival Analysis | 1 | 1995 | 298 | 0.030 |
Why?
|
Transcription, Genetic | 3 | 1999 | 108 | 0.030 |
Why?
|
Recurrence | 1 | 1995 | 350 | 0.030 |
Why?
|
Therapeutic Irrigation | 3 | 1998 | 66 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2011 | 676 | 0.030 |
Why?
|
False Positive Reactions | 1 | 1993 | 33 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 1995 | 324 | 0.030 |
Why?
|
Diagnostic Errors | 1 | 1993 | 40 | 0.030 |
Why?
|
Aging | 1 | 2003 | 1594 | 0.030 |
Why?
|
Pneumocystis | 1 | 1992 | 1 | 0.030 |
Why?
|
Eye | 1 | 1992 | 10 | 0.030 |
Why?
|
Didanosine | 1 | 1992 | 6 | 0.030 |
Why?
|
Papillomaviridae | 2 | 2005 | 29 | 0.030 |
Why?
|
Measles Vaccine | 1 | 1991 | 2 | 0.030 |
Why?
|
Ophthalmoscopy | 1 | 1991 | 1 | 0.030 |
Why?
|
Eye Infections, Viral | 1 | 1991 | 2 | 0.030 |
Why?
|
Drug Evaluation | 1 | 1991 | 52 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 1991 | 56 | 0.030 |
Why?
|
Leukocyte Count | 1 | 1991 | 92 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 1991 | 80 | 0.030 |
Why?
|
Administration, Oral | 1 | 1991 | 140 | 0.020 |
Why?
|
Phytohemagglutinins | 1 | 2011 | 9 | 0.020 |
Why?
|
Neutrophil Activation | 1 | 2011 | 7 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2011 | 78 | 0.020 |
Why?
|
Cell Survival | 1 | 2011 | 169 | 0.020 |
Why?
|
Medication Therapy Management | 1 | 2009 | 4 | 0.020 |
Why?
|
Prevalence | 1 | 1991 | 491 | 0.020 |
Why?
|
Medication Errors | 1 | 2009 | 16 | 0.020 |
Why?
|
Pharmacists | 1 | 2009 | 16 | 0.020 |
Why?
|
Lung Diseases, Fungal | 1 | 2009 | 9 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2009 | 33 | 0.020 |
Why?
|
Quadriceps Muscle | 1 | 2009 | 27 | 0.020 |
Why?
|
Transcription Factor AP-1 | 2 | 1999 | 16 | 0.020 |
Why?
|
Nurses | 1 | 2009 | 46 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2008 | 16 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2008 | 35 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2008 | 32 | 0.020 |
Why?
|
Antigens, CD | 2 | 1999 | 99 | 0.020 |
Why?
|
Radiography | 1 | 2009 | 678 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2011 | 1113 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 1991 | 1184 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2009 | 349 | 0.020 |
Why?
|
T-Lymphocytes | 2 | 1997 | 212 | 0.020 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2005 | 1 | 0.020 |
Why?
|
Brain | 1 | 2015 | 1687 | 0.020 |
Why?
|
Toll-Like Receptors | 1 | 2005 | 28 | 0.020 |
Why?
|
Immunity, Mucosal | 1 | 2005 | 29 | 0.020 |
Why?
|
Mucous Membrane | 1 | 2005 | 40 | 0.020 |
Why?
|
Toll-Like Receptor 2 | 1 | 2005 | 32 | 0.020 |
Why?
|
Toll-Like Receptor 4 | 1 | 2005 | 33 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 265 | 0.020 |
Why?
|
Gene Expression | 1 | 2005 | 226 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2005 | 323 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2008 | 770 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 1220 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2004 | 70 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 227 | 0.010 |
Why?
|
Phenotype | 1 | 2003 | 357 | 0.010 |
Why?
|
Calgranulin A | 1 | 2001 | 4 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2002 | 90 | 0.010 |
Why?
|
HIV Wasting Syndrome | 1 | 2000 | 3 | 0.010 |
Why?
|
Electric Impedance | 1 | 2000 | 24 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2001 | 193 | 0.010 |
Why?
|
Body Weight | 1 | 2000 | 133 | 0.010 |
Why?
|
Stomatitis, Aphthous | 1 | 1999 | 1 | 0.010 |
Why?
|
Mycoplasma | 1 | 1999 | 4 | 0.010 |
Why?
|
Jurkat Cells | 1 | 1999 | 10 | 0.010 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 1999 | 7 | 0.010 |
Why?
|
Chemical Fractionation | 1 | 1999 | 7 | 0.010 |
Why?
|
Solubility | 1 | 1999 | 36 | 0.010 |
Why?
|
Fetal Blood | 1 | 1999 | 16 | 0.010 |
Why?
|
Pneumococcal Vaccines | 1 | 1999 | 5 | 0.010 |
Why?
|
Immunization | 1 | 1999 | 47 | 0.010 |
Why?
|
Hepatitis C Antibodies | 1 | 1998 | 7 | 0.010 |
Why?
|
Virus Integration | 1 | 1998 | 9 | 0.010 |
Why?
|
Substance Abuse, Intravenous | 1 | 1998 | 12 | 0.010 |
Why?
|
Transfusion Reaction | 1 | 1998 | 9 | 0.010 |
Why?
|
Chemokine CCL4 | 1 | 1998 | 8 | 0.010 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 1998 | 9 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2000 | 638 | 0.010 |
Why?
|
Chemokine CCL3 | 1 | 1998 | 12 | 0.010 |
Why?
|
Vaginitis | 1 | 1998 | 4 | 0.010 |
Why?
|
Tumor Virus Infections | 1 | 1998 | 15 | 0.010 |
Why?
|
Chemokine CCL5 | 1 | 1998 | 17 | 0.010 |
Why?
|
HIV Envelope Protein gp120 | 1 | 1998 | 19 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1998 | 145 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 130 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1998 | 321 | 0.010 |
Why?
|
Heating | 1 | 1997 | 3 | 0.010 |
Why?
|
Odds Ratio | 1 | 1998 | 285 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 1998 | 324 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 1997 | 19 | 0.010 |
Why?
|
Endopeptidases | 1 | 1997 | 29 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1997 | 24 | 0.010 |
Why?
|
Vaccination | 1 | 1997 | 41 | 0.010 |
Why?
|
CD55 Antigens | 1 | 1996 | 2 | 0.010 |
Why?
|
Staphylococcal Protein A | 1 | 1996 | 2 | 0.010 |
Why?
|
CD59 Antigens | 1 | 1996 | 3 | 0.010 |
Why?
|
Immunosorbent Techniques | 1 | 1996 | 4 | 0.010 |
Why?
|
Membrane Cofactor Protein | 1 | 1996 | 3 | 0.010 |
Why?
|
Virion | 1 | 1996 | 13 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 1997 | 209 | 0.010 |
Why?
|
Apoptosis | 1 | 1997 | 251 | 0.010 |
Why?
|
Quality of Life | 1 | 1999 | 664 | 0.010 |
Why?
|
Drug Tolerance | 1 | 1992 | 12 | 0.010 |
Why?
|